Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/FCF ratio high or low?
The EV/FCF ratio of 0.07x is 98% below its estimated 1-year average of 3.71x, near the low end of its estimated 1-year range (0.07x–4.47x).
As of 2026-10-06T18:02:08.635Z.
Calculation as of: 2026-10-06T18:02:08.635Z.
Quote observation: 2026-10-06T17:54:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f5b5977bdf8e8744ccf3bd9773e74661520241b62ab886de63a55e038e5fa23
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
0.07x
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
24.95x
median of 204 covered companies
CURRENT VS SECTOR MEDIAN
-99.72%
vs the sector median at left
Market Cap
$141.00M
EV/FCF Ratio
N/A
TTM Avg
31.12x
3Y Avg
31.12x
5Y Avg
31.12x
Market Cap
$137.11M
EV/FCF Ratio
501.24x
TTM Avg
1051.55x
3Y Avg
1051.55x
5Y Avg
1051.55x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. (FBIOP) | $140.52M | 0.07x | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $140.31M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $141.00M | N/A | 31.12x | 31.12x | 31.12x |
| Alpha Cognition Inc (ACOG)vs › | $138.93M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $142.76M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.10M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.11M | 501.24x | 1051.55x | 1051.55x | 1051.55x |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.57M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $135.33M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $135.14M | N/A | N/A | N/A | N/A |
EV/FCF
0.1x
P/FCF
1.1x
FCF Yield
89.55%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2026-10-05 | 4.28x |
| 2026-10-02 | 3.91x |
| 2026-10-01 | 3.68x |
| 2026-09-30 | 3.81x |
| 2026-09-29 | 3.86x |
| 2026-09-28 | 3.81x |
| 2026-09-25 | 3.85x |
| 2026-09-24 | 3.90x |
| 2026-09-23 | 3.97x |
| 2026-09-22 | 4.00x |
| 2026-09-21 | 4.03x |
| 2026-09-18 | 4.19x |
| 2026-09-17 | 4.22x |
| 2026-09-16 | 4.28x |
| 2026-09-15 | 4.30x |
| 2026-09-14 | 4.38x |
| 2026-09-11 | 4.38x |
| 2026-09-10 | 4.42x |
| 2026-09-09 | 4.42x |
| 2026-09-08 | 4.44x |
| 2026-09-04 | 4.47x |
| 2026-09-03 | 4.41x |
| 2026-09-02 | 4.46x |
| 2026-09-01 | 4.39x |
| 2026-08-31 | 4.46x |
| 2026-08-28 | 4.43x |
| 2026-08-27 | 4.41x |
| 2026-08-26 | 4.36x |
| 2026-08-25 | 4.34x |
| 2026-08-24 | 4.36x |
| 2026-08-21 | 4.34x |
| 2026-08-20 | 4.33x |
| 2026-08-19 | 4.31x |
| 2026-08-18 | 4.31x |
| 2026-08-17 | 4.29x |
| 2026-08-14 | 4.44x |
| 2026-08-13 | 3.37x |
| 2026-08-12 | 3.42x |
| 2026-08-11 | 3.50x |
| 2026-08-10 | 3.45x |
| 2026-08-07 | 3.56x |
| 2026-08-06 | 3.58x |
| 2026-08-05 | 3.39x |
| 2026-08-04 | 3.33x |
| 2026-08-03 | 3.34x |
| 2026-07-31 | 3.32x |
| 2026-07-30 | 3.30x |
| 2026-07-29 | 3.30x |
| 2026-07-28 | 3.29x |
| 2026-07-27 | 3.30x |
| 2026-07-24 | 3.32x |
| 2026-07-23 | 3.31x |
| 2026-07-22 | 3.32x |
| 2026-07-21 | 3.29x |
| 2026-07-20 | 3.28x |
| 2026-07-17 | 3.28x |
| 2026-07-16 | 3.25x |
| 2026-07-15 | 3.30x |
| 2026-07-14 | 3.29x |
| 2026-07-13 | 3.27x |
| 2026-07-10 | 3.24x |
| 2026-07-09 | 3.30x |
| 2026-07-08 | 3.36x |
| 2026-07-07 | 3.56x |
| 2026-07-06 | 3.65x |
| 2026-07-02 | 3.69x |
| 2026-07-01 | 3.65x |
| 2026-06-30 | 3.62x |
| 2026-06-29 | 3.61x |
| 2026-06-26 | 3.60x |
| 2026-06-25 | 3.63x |
| 2026-06-24 | 3.62x |
| 2026-06-23 | 3.59x |
| 2026-06-22 | 3.57x |
| 2026-06-18 | 3.61x |
| 2026-06-17 | 3.72x |
| 2026-06-16 | 3.65x |
| 2026-06-15 | 3.81x |
| 2026-06-12 | 3.76x |
| 2026-06-11 | 3.71x |
| 2026-06-10 | 3.62x |
| 2026-06-09 | 3.64x |
| 2026-06-08 | 3.64x |
| 2026-06-05 | 3.75x |
| 2026-06-04 | 3.85x |
| 2026-06-03 | 3.78x |
| 2026-06-02 | 3.70x |
| 2026-06-01 | 3.71x |
| 2026-05-29 | 3.46x |
| 2026-05-28 | 3.44x |
| 2026-05-27 | 3.33x |
| 2026-05-26 | 3.16x |
| 2026-05-22 | 2.79x |
| 2026-05-21 | 2.69x |
| 2026-05-20 | 2.67x |
| 2026-05-19 | 2.64x |
| 2026-05-18 | 2.64x |
| 2026-05-15 | 2.37x |
